指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

丁丙诺啡制剂:围手术期管理临床最佳实践策略建议

Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures.
指南 / 共识 · Pain Physician · 2018-01-01
一句话结论丁丙诺啡围手术期管理需个体化,考虑手术类型、患者特征、制剂和适应证,选择继续用药、停药或桥接替代阿片类药物。

本文为丁丙诺啡制剂围手术期管理的临床最佳实践策略建议。通过PubMed检索,纳入1项随机对照试验、1项前瞻性匹配队列、1项回顾性队列、4篇病例报告和6篇综述,共12篇文章。文章总结了丁丙诺啡独特的药效和药代动力学特点及其对围手术期镇痛的挑战,提出围手术期管理需考虑手术性质(术后阿片需求、择期或急诊)、患者特征、丁丙诺啡制剂和用药适应证,可选方案包括继续丁丙诺啡治疗或停药一段时间伴或不伴桥接替代阿片类药物,同时应优化社会支持和患者动机,并最大化使用非阿片类辅助治疗。由于仅纳入12篇文章,本综述所能提供的推荐有限。

要点

  • 丁丙诺啡围手术期管理需考虑手术性质(术后阿片需求、择期或急诊)、患者特征、丁丙诺啡制剂和用药适应证。
  • 管理选项包括继续丁丙诺啡治疗或停药一段时间,伴或不伴桥接替代阿片类药物。
  • 应优化社会支持人员和患者动机,并最大化使用非阿片类辅助治疗。
  • 仅纳入12篇文章,本综述提供的推荐有限。

适用人群与场景

  • 正在接受丁丙诺啡治疗且计划进行手术或介入性疼痛操作的患者。

处置流程与药物剂量

  • 围手术期管理需考虑手术性质(术后阿片需求、择期或急诊)、患者特征、丁丙诺啡制剂和用药适应证。
  • 管理选项包括继续丁丙诺啡治疗或停药一段时间,伴或不伴桥接替代阿片类药物。
  • 应优化社会支持人员和患者动机。
  • 应最大化使用非阿片类辅助治疗(根据每位患者情况适用)。

研究设计与关键结果

  • PubMed检索纳入1项随机对照试验、1项前瞻性匹配队列、1项回顾性队列、0项病例系列、4篇病例报告和6篇综述,共12篇文章。
  • 对关键文献进行了回顾和总结。

证据类型、等级与局限

  • 证据类型:综述(基于文献检索的临床最佳实践策略建议)。
  • 局限:仅纳入12篇文章,所能提供的推荐有限。

对床旁实践的改变

  • 面对正在使用丁丙诺啡且需手术或介入性疼痛操作的患者,需根据手术性质、患者特征、制剂和适应证制定个体化围手术期管理计划。
  • 作者建议优化社会支持和患者动机,并最大化使用非阿片类辅助治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Starting with approval for clinical use in the treatment of opioid dependence in October 2002 by the Food and Drug Administration (FDA), buprenorphine has become an integral treatment option and in recent years, in chronic pain management. Buprenorphine possesses a unique pharmacodynamic and pharmacokinetic profile that can potentially make perioperative analgesia challenging.

OBJECTIVES: To date no unified guidelines or recommendations are available for buprenorphine product management during the perioperative period. The present investigation aims to review the literature and provide recommendations when encountering a patient on buprenorphine therapy who is scheduled for a surgical or interventional pain procedure.

METHODS: Clinical studies and reviews were searched using the PubMed National Center for Biotechnology Information database using MeSH terms buprenorphine, buprenorphine and naloxone, suboxone, perioperative, and postoperative pain.

RESULTS: PubMed National Center for Biotechnology Information database search resulted in one randomized control trial, one prospective case matched cohort, one retrospective cohort, 0 case series, 4 case reports, and 6 review articles. Key literature is reviewed and summarized.

LIMITATIONS: Only 12 articles were included, which permits only limited recommendations drawn from this review.

CONCLUSIONS: The perioperative management of buprenorphine and buprenorphine/naloxone are dependent on several key factors. The nature of the surgery, namely the postoperative opioid requirement, elective versus emergency surgery, patient characteristics, formulation of buprenorphine, and indication for buprenorphine or buprenorphine/naloxone therapy must be considered when devising a plan. Several options exist when formulating a plan for the perioperative management, including continuing buprenorphine therapy or holding buprenorphine therapy for a defined period of time with or without bridging to alternative opioids. Additionally, social support people and patient motivation should be addressed and optimized, as well as nonopioid adjuvant therapy should be maximized as applicable to each patient undergoing a surgical or interventional pain procedure.

KEY WORDS: Buprenorphine, naloxone, surgery, pain management, anesthesia, suboxone, opioid abuse.

来源:Pain Physician,查看原文。版权归原作者所有。

参考来源

  1. Jonan AB, Kaye AD, Urman RD, et al. Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures. Pain Physician. 2018. PMID: 29357325

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。